. 1 The goal of CER-CI is to establish a consensus-based set of principles and tools to guide the design and evaluation of nonexperimental studies, including prospective and retrospective observational designs, so that the knowledge gained from these studies can be applied to improve patient health outcomes. 2 Health care reform has set the stage for this dialogue, and to best use the opportunity, participants need to understand how payers that assess pharmaceutical technology currently view observational study designs and which factors affect their credibility for this audience.
Several federal agencies have articulated definitions of comparative effectiveness research (CER). 3 These definitions are broad in scope and include prospective and retrospective observational studies, a potentially rich source of information heretofore underutilized by payers in evaluating drugs and medical technologies. Observational designs have 2 obvious advantages. First, they provide "real world" information that complements data from traditional randomized controlled clinical trials (RCTs). Observational studies let us see the behaviors of practitioners and patients that are not being managed by structured protocols. Adherence tends to be unrealistically high because patients know they are being observed; in fact, RCTs often directly encourage adherence. Second, observational studies tend to be more efficient than RCTs because their designs are less costly, and retrospective studies can obtain in a few months or less outcomes data that would take years to collect prospectively.
The most important limitation of observational studies is confounding, particularly channeling bias. This is likely to occur when providers believe that a drug should be used preferentially in a subset of patients in the study. For example, an observational study might find a greater incidence of myocardial infarction in patients receiving angiotensin-converting enzyme (ACE) inhibitors that may be influenced by treatment guidelines recommending use of ACE inhibitors in patients with diabetes, who are known to have a higher risk of cardiac events; the investigators could control for this confounder. 4 Methods of controlling confounding have been developed, usually by propensity scoring or instrumental variables, but are limited by the ability to identify and control for the potential sources of bias. Retrospective observational studies are especially attractive because they yield the most information in the shortest possible time, but they are subject to recall bias and measurement bias, both of which can be controlled in a welldesigned prospective study.
Managed care pharmacists and medical directors traditionally have not accepted observational studies as high-grade evidence. This is consistent with commonly used published evidence grading schemes that assign lower grades to all nonrandomized studies. 5, 6 These study designs evoke skepticism from payers, as the results of the NPC survey demonstrate. Payers often cite as an example the Women's Health Initiative (WHI), a large RCT whose results contradicted prior epidemiologic studies and questioned the net benefit versus harm of hormone replacement therapy (HRT). 7 The principal investigator recently offered an explanation that reconciles the results of both types of studies and illustrates the pitfalls of relying entirely on one type. WHI's RCT had a shorter duration of follow up compared with prior epidemiologic studies but showed an elevated risk of coronary heart disease (CHD) in the first 2-3 years of HRT. Observational studies underreported early CHD events but counted events later in the patient's life that would be missed in an RCT. Since most of the CHD risk occurs in the first 2 years after HRT initiation, the epidemiologic studies had underestimated CHD risk, suggesting that there was a net CHD benefit. Considering the results of both types of studies led to a more complete understanding of the drug's impact on this complex chronic disease and increased our confidence in the recommendation not to treat. 8 This example demonstrates the value of considering evidence from both RCTs and observational studies, but such arguments do little to convince skeptical payers to use observational studies. A previous roundtable discussion identified the lack of credible practical tools to evaluate these studies as a barrier to acceptance. 9 Because observational designs are less rigidly structured than traditional RCTs, health plan pharmacists worry that the data are being manipulated, especially in manufacturer-sponsored projects. CER-CI will develop standard methodology that is more transparent and facilitates critical evaluation of the results.
There is a need to improve the quantity of CER studies as well as their quality. Bourgeois and colleagues (2012) analyzed the prevalence of CER among studies registered at www. clinicaltrials.gov. 10 The The proportion of individuals contacted that submitted responses reflects the importance of this subject to health plan pharmacy and medical directors, but the sample is still small compared with the total number of health plans that perform pharmaceutical technology assessment internally, which is the true denominator. This number may be hard to determine, since many smaller plans delegate part or all of the formulary management process to pharmacy benefit management companies. The authors note that variation in state rules and internal health plan structures may limit generalizability of the results. Considering these limitations, it may be difficult if not impossible to obtain a properly stratified random sample.
Self-selection bias is also likely. The authors did not state how often the respondent was the person first contacted and how many respondents passed the survey on to a coworker. The authors report that 24% of those contacted did not respond, which is good for this type of survey, but still indicates potential selection bias. The respondents would be those most interested in the subject and probably most knowledgeable, resulting in overestimation of the level of skill and sophistication of the overall population.
It would have been helpful to CER-CI if the survey had asked some additional questions aimed at understanding more clearly the factors that the respondents consider when grading different types of evidence and the logic they used in ranking them in the responses to the present survey. Since the respondents actually ranked some tertiary sources higher in importance than primary observational studies, it would be informative to have more insight into the reasons for the rankings.
Notwithstanding these limitations, the authors are to be commended for taking on a complex project, providing a baseline for assessing the impact of the CER-CI initiative, and measuring the extent to which it improves payer acceptance of observational studies by standardizing methodology and improving transparency. If possible, further study along the lines described above would be a valuable addition to the collaborative's knowledge base. comparator), and 72% of these were not manufacturer-funded. 10 The low prevalence of CER among these studies demonstrates the evidence gap and suggests that a substantial increase in CER studies, both RCT and observational, is needed to provide the evidence required by decision makers. Manufacturers have been reluctant to fund CER studies because they risk getting an unfavorable outcome, as occurred in the PROVE-IT-TIMI (Pravastatin or Atorvastatin Evaluation and Infection TherapyThrombolysis in Myocardial Infarction) 22 trial, which was funded by the manufacturer of pravastatin to demonstrate its noninferiority to atorvastatin in post-acute coronary syndrome patients, but in fact found a modest superiority of atorvastatin.
11 This places a greater burden on governmental and private nonmanufacturer sources to fund CER.
To evaluate the results of the initiative, a baseline survey of payer attitudes and practices is necessary, but doing it well is challenging. The diversity of payer opinions, increasing demands on their time, and the very broad inclusive definition of CER by federal agencies complicate the task. For example, the formulary review process in our health plan does not consider manufacturers' dossiers as evidence per se, rather as a catalogue of available evidence, the contents of which must be confirmed by independent searches of primary literature. The federal definitions of CER include tertiary sources such as published systematic reviews, health technology assessments by government agencies, and evidence-based clinical practice guidelines.
Surprisingly, the respondents in the NPC survey ranked tertiary sources that may not be explicitly evidence-based, such as nonsystematic reviews, expert consensus practice guidelines, and medical society position statements, above observational studies. Clearly, the proponents of observational studies have some work to do. Amongst observational studies, internal claims database analyses ranked highest despite often including only pharmacy claims and sometimes lacking rigorous statistical analysis. When inclusion criteria are applied, it is difficult to achieve adequate power using internal data, except perhaps in the largest national health plans. It is not clear what criteria are driving this ranking by payers. Further survey work with a revised set of questions could be useful to the CER-CI team.
The authors of this JMCP article on formulary management identified selection bias as a major limitation. 1 This study used a stratified convenience sample with multiple recruitment methods. Although this method may reduce selection bias compared with recruiting from a single group such as AMCP members, the sample probably is still not representative of all U.S. payers, due to the use of professional relationships and research organization databases to recruit subjects. Pairing data from a medical director and a pharmacy director at the same plan could be useful to study the diversity of opinion within organizations, but the sample of 6 plans is too small to
